We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

115 hedge funds and large institutions have $232M invested in Palvella Therapeutics in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 54 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

391% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 11

300% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 9

30% more capital invested

Capital invested by funds: $179M → $232M (+$53.7M)

28% more funds holding

Funds holding: 90 → 115 (+25)

0.13% more ownership

Funds ownership: 0.66% → 0.79% (+0.13%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

75% less call options, than puts

Call options by funds: $244K | Put options by funds: $973K

Holders
115
Holders Change
+25
Holders Change %
+27.78%
% of All Funds
2.64%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
36
Increased
54
Reduced
11
Closed
9
Calls
$244K
Puts
$973K
Net Calls
-$729K
Net Calls Change
-$600K

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$10.4M
2
Millennium Management
Millennium Management
New York
+$8.7M
3
BI
BVF Inc
California
+$7.5M
4
Renaissance Technologies
Renaissance Technologies
New York
+$6.81M
5
Morgan Stanley
Morgan Stanley
New York
+$5.68M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$13.2M
2
BIM
Bogle Investment Management
Massachusetts
-$1.25M
3
LOAMU
Lombard Odier Asset Management (USA)
New York
-$1.23M
4
OFM
Omega Fund Management
Massachusetts
-$974K
5
Two Sigma Investments
Two Sigma Investments
New York
-$734K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCP
26
Tourbillon Capital Partners
New York
$2.01M +$2.28M +3,689 New
VIA
27
Vident Investment Advisory
Georgia
$1.86M +$596K +963 +37%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$1.73M +$412K +665 +27%
FQ
29
First Quadrant
California
$1.71M +$1.25M +2,020 +182%
3C
30
361 Capital
Colorado
$1.51M +$1.72M +2,777 New
Bank of New York Mellon
31
Bank of New York Mellon
New York
$1.33M +$905K +1,462 +151%
Vanguard Group
32
Vanguard Group
Pennsylvania
$1.32M +$621K +1,003 +70%
Deutsche Bank
33
Deutsche Bank
Germany
$1.31M +$145K +234 +11%
Cerity Partners
34
Cerity Partners
New York
$1.3M +$232K +375 +19%
Allianz Asset Management
35
Allianz Asset Management
Germany
$1.28M +$1.45M +2,343 New
JP Morgan Chase
36
JP Morgan Chase
New York
$1.25M +$728K +1,176 +106%
Baird Financial Group
37
Baird Financial Group
Wisconsin
$1.15M +$810K +1,309 +166%
DZ Bank
38
DZ Bank
Germany
$1.02M +$1.16M +1,875 New
PPA
39
Parametric Portfolio Associates
Washington
$949K +$1.08M +1,739 New
WCM
40
Wedge Capital Management
North Carolina
$900K +$1.02M +1,649 New
Ameriprise
41
Ameriprise
Minnesota
$880K +$998K +1,613 New
VEA
42
Virtus ETF Advisers
New York
$857K +$530K +856 +120%
EGI
43
EAM Global Investors
California
$857K +$972K +1,570 New
PIM
44
Platinum Investment Management
Australia
$847K +$961K +1,553 New
Invesco
45
Invesco
Georgia
$812K +$921K +1,488 New
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$790K +$630K +1,018 +237%
AllianceBernstein
47
AllianceBernstein
Tennessee
$724K +$691K +1,116 +531%
Two Sigma Advisers
48
Two Sigma Advisers
New York
$663K +$451K +728 +149%
BIM
49
Bogle Investment Management
Massachusetts
$656K -$1.25M -2,020 -63%
AG
50
Algert Global
California
$644K +$731K +1,181 New
1
2
3 4 5

PVLA Hedge Fund Activity: Q1 2018 in Review

115 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2018, worth a combined $232M — up 30% from $179M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new PVLA positions and 9 closed out — a net gain of 27 holders — while 54 added to existing stakes and 11 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $10.4M. The largest seller was OrbiMed, cutting an estimated $13.2M.

  • 115 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2018, up from 90 in Q4 2017.
  • Funds reported $232M of Palvella Therapeutics stock for Q1 2018, up 30% quarter-over-quarter.
  • 36 funds opened new Palvella Therapeutics positions in Q1 2018 and 9 closed out, a net change of +27 holders.
  • The largest Palvella Therapeutics buyer in Q1 2018 was Acadian Asset Management, an estimated $10.4M added.
  • The largest Palvella Therapeutics seller in Q1 2018 was OrbiMed, an estimated $13.2M sold.

Based on aggregated 13F filings for Q1 2018.